These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 1564764)

  • 21. HA-1A. A human monoclonal antibody for the treatment of gram-negative sepsis.
    Smith CR; Straube RC; Ziegler EJ
    Infect Dis Clin North Am; 1992 Mar; 6(1):253-66. PubMed ID: 1578120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group.
    Greenman RL; Schein RM; Martin MA; Wenzel RP; MacIntyre NR; Emmanuel G; Chmel H; Kohler RB; McCarthy M; Plouffe J
    JAMA; 1991 Aug; 266(8):1097-102. PubMed ID: 1865542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent developments in our understanding of sepsis: evaluation of anti-endotoxin antibodies and biological response modifiers.
    Talan DA
    Ann Emerg Med; 1993 Dec; 22(12):1871-90. PubMed ID: 8239111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical trials of immunotherapy for sepsis.
    Cunnion RE
    Crit Care Med; 1992 Jun; 20(6):721-3. PubMed ID: 1597020
    [No Abstract]   [Full Text] [Related]  

  • 25. [A cost-effectiveness analysis of treatment with antiendotoxin monoclonal antibodies in gram-negative sepsis].
    Tebas P
    Med Clin (Barc); 1993 Dec; 101(19):757-8. PubMed ID: 8289526
    [No Abstract]   [Full Text] [Related]  

  • 26. Cost-effectiveness of monoclonal antibodies to gram-negative endotoxin in the treatment of gram-negative sepsis in ICU patients.
    Chalfin DB; Holbein ME; Fein AM; Carlon GC
    JAMA; 1993 Jan; 269(2):249-54. PubMed ID: 8417245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Observations using antiendotoxin antibody (E5) as adjuvant therapy in humans with suspected, serious, gram-negative sepsis.
    Greenberg RN; Wilson KM; Kunz AY; Wedel NI; Gorelick KJ
    Crit Care Med; 1992 Jun; 20(6):730-5. PubMed ID: 1597023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Introduction of immunotherapeutic agents in clinical practice; current status concerning anti-endotoxin antibody HA-1A in the control of sepsis].
    van Deventer SJ; van der Linden CJ; Roord JJ; Schellekens H; Schellekens JF
    Ned Tijdschr Geneeskd; 1993 Feb; 137(7):334-6. PubMed ID: 8437630
    [No Abstract]   [Full Text] [Related]  

  • 29. The role of monoclonal antibodies in the management of gram-negative sepsis. Experience with the E5 antibody.
    Gorelick KJ; Chmel H
    Infect Dis Clin North Am; 1991 Dec; 5(4):899-913. PubMed ID: 1783775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.
    Ziegler EJ; Fisher CJ; Sprung CL; Straube RC; Sadoff JC; Foulke GE; Wortel CH; Fink MP; Dellinger RP; Teng NN
    N Engl J Med; 1991 Feb; 324(7):429-36. PubMed ID: 1988827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
    Barriere SL; Guglielmo BJ
    Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A cost-efficacy analysis of treatment with antiendotoxin monoclonal antibodies in gram-negative sepsis].
    Badía X; Segú L; García Alonso F; Rovira J
    Med Clin (Barc); 1993 Jan; 100(3):84-9. PubMed ID: 8426499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monoclonal antibody therapy for gram-negative sepsis: principles, applications, and controversies.
    Mehra IV; Gottlieb JE; Nash DB
    Pharmacotherapy; 1993; 13(2):128-34. PubMed ID: 8469619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adoptive immunotherapy of gram-negative sepsis: use of monoclonal antibodies to lipopolysaccharide.
    Fink MP
    Crit Care Med; 1993 Feb; 21(2 Suppl):S32-9. PubMed ID: 8428494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoclonal antibodies to endotoxin. New allies against sepsis?
    Bone RC
    JAMA; 1991 Aug; 266(8):1125-6. PubMed ID: 1865548
    [No Abstract]   [Full Text] [Related]  

  • 36. [Immunotherapy of severe gram-negative bacterial infections. Centoxin: a new drug under monitoring. National Committee for the Evaluation of Centoxin].
    Pathol Biol (Paris); 1992 Dec; 40(10):975-6. PubMed ID: 1299810
    [No Abstract]   [Full Text] [Related]  

  • 37. Monoclonal antibodies and the treatment of gram-negative bacteremia and shock.
    Wolff SM
    N Engl J Med; 1991 Feb; 324(7):486-8. PubMed ID: 1988835
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.
    McCloskey RV; Straube RC; Sanders C; Smith SM; Smith CR
    Ann Intern Med; 1994 Jul; 121(1):1-5. PubMed ID: 8198341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Life-saving immunotherapy with cross-reactive monoclonal antibodies against endotoxin: a critical evaluation of experimental and clinical studies.
    Cornelissen JJ; Schellekens JF; Kraaijeveld CA; Verhoef J
    Neth J Med; 1991 Oct; 39(3-4):170-6. PubMed ID: 1791879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Another negative clinical trial of a new agent for the treatment of sepsis: rethinking the process of developing adjuvant treatments for serious infections.
    Fink MP
    Crit Care Med; 1995 Jun; 23(6):989-91. PubMed ID: 7774236
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.